| Comparative transfection of DNA into primary and transformed mammalian cells from different lineages R Maurisse, D De Semir, H Emamekhoo, B Bedayat, A Abdolmohammadi, ... BMC biotechnology 10, 1-9, 2010 | 266 | 2010 |
| Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology T Gilligan, DW Lin, R Aggarwal, D Chism, N Cost, IH Derweesh, ... Journal of the National Comprehensive Cancer Network 17 (12), 1529-1554, 2019 | 230 | 2019 |
| Management of metastatic clear cell renal cell carcinoma: ASCO guideline WK Rathmell, RB Rumble, PJ Van Veldhuizen, H Al-Ahmadie, ... Journal of Clinical Oncology 40 (25), 2957-2995, 2022 | 146 | 2022 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 127 | 2022 |
| HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer M Alyamani, H Emamekhoo, S Park, J Taylor, N Almassi, S Upadhyay, ... The Journal of clinical investigation 128 (8), 3333-3340, 2018 | 50 | 2018 |
| Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer JM Sperger, H Emamekhoo, RR McKay, CN Stahlfeld, A Singh, XE Chen, ... Journal of Clinical Oncology 39 (26), 2926, 2021 | 46 | 2021 |
| Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing … MC Ornstein, CM Diaz-Montero, P Rayman, P Elson, S Haywood, ... Urologic Oncology: Seminars and Original Investigations 36 (9), 405-412, 2018 | 44 | 2018 |
| Safety and efficacy of nivolumab plus ipilimumab (NIVO+ IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920. H Emamekhoo, M Olsen, BC Carthon, A Drakaki, IJ Percent, AM Molina, ... Journal of Clinical Oncology 37 (15_suppl), 4517-4517, 2019 | 39 | 2019 |
| Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study VS Koshkin, N Henderson, M James, D Natesan, D Freeman, A Nizam, ... Cancer 128 (6), 1194-1205, 2022 | 38 | 2022 |
| Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: a phase 2 randomized clinical trial SK Pal, PH Frankel, A Mortazavi, M Milowsky, U Vaishampayan, M Parikh, ... JAMA oncology 7 (10), 1536-1543, 2021 | 31 | 2021 |
| ATM/RB1 mutations predict shorter overall survival in urothelial cancer M Yin, P Grivas, H Emamekhoo, P Mendiratta, S Ali, JA Hsu, M Vasekar, ... Oncotarget 9 (24), 16891, 2018 | 30 | 2018 |
| Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA trial CH Lee, R Motzer, H Emamekhoo, M Matrana, I Percent, JJ Hsieh, ... Clinical cancer research 28 (15), 3248-3255, 2022 | 29 | 2022 |
| ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839)+ everolimus (E) vs placebo (pbo)+ E in patients (pts) with advanced/metastatic renal cell … RJ Motzer, CH Lee, H Emamekhoo, M Matrana, JJ Hsieh, A Hussain, ... Annals of Oncology 30, v889-v890, 2019 | 27 | 2019 |
| Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920 H Emamekhoo, MR Olsen, BC Carthon, A Drakaki, IJ Percent, AM Molina, ... Cancer 128 (5), 966-974, 2022 | 26 | 2022 |
| Immunological correlates of response to immune checkpoint inhibitors in metastatic urothelial carcinoma A Tzeng, CM Diaz-Montero, PA Rayman, JS Kim, PG Pavicic, JH Finke, ... Targeted Oncology 13, 599-609, 2018 | 26 | 2018 |
| Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) DG McNeel, JC Eickhoff, E Wargowski, LE Johnson, CE Kyriakopoulos, ... Journal for Immunotherapy of Cancer 10 (3), 2022 | 24 | 2022 |
| Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma M Bootsma, RR McKay, H Emamekhoo, RM Bade, JL Schehr, ... Journal of Clinical Oncology 40 (31), 3633, 2022 | 21 | 2022 |
| Prognostic value of DNA damage response genomic alterations in relapsed/advanced urothelial cancer M Yin, P Grivas, QE Wang, A Mortazavi, H Emamekhoo, SL Holder, ... The Oncologist 25 (8), 680-688, 2020 | 20 | 2020 |
| Prognostic factors and risk stratification in invasive upper tract urothelial carcinoma H Emamekhoo, P Dhillon, D Gopalakrishnan, P Elson, A Stephenson, ... Clinical Genitourinary Cancer 16 (4), e751-e760, 2018 | 20 | 2018 |
| PARP inhibitors in metastatic prostate cancer AK Taylor, D Kosoff, H Emamekhoo, JM Lang, CE Kyriakopoulos Frontiers in Oncology 13, 1159557, 2023 | 19 | 2023 |
